Could the same technology that enables targeted immunotherapy for cancer be used to tackle Alzheimer’s?

Inspired by advances in cancer therapy, a team at the Buck Institute has engineered immune cells equipped with specialized targeting devices called chimeric antigen receptors (CARs) that can distinguish and respond to tau tangles and various forms of toxic amyloid plaques, both of which are implicated in Alzheimer’s disease pathology.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup